Back to UBS Group AG UBS Group AG

LIXTLIXT
Showing 8 of 23 quarters

Position history for UBS Group AGUBS Group AG's holdings in LIXTE BIOTECHNOLOGY HLDGS IN

UBS Group AG holds 6,400 shares of LIXT (LIXTE BIOTECHNOLOGY HLDGS IN), worth $47,488 as of 2026-Q2. This is a new position.

Current Value

$47,488

Current Shares

6,400

Total Value Change

+$46,802

Total Shares Change

+6,033

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
New
6,400
-
$47,4880.0%$7.42
31
2026-Q1
Exited
0
-100.0%
$00.0%$2.85
0
2025-Q4
Decreased
756
-95.5%
$2,9710.0%$3.90
0
2025-Q3
Increased
16,747
+1406.0%
$84,2370.0%$5.19
24
2025-Q2
Decreased
1,112
-86.6%
$1,0060.0%$0.71
0
2025-Q1
Increased
8,291
+323.9%
$10,0320.0%$1.27
19
2024-Q4
Increased
1,956
+433.0%
$3,9710.0%$2.00
16
2024-Q3
Increased
367
+6.4%
$6860.0%$1.91
8

Other major holders of LIXT: VANGUARD CAPITAL MANAGEMENT LLC, SCOTIA CAPITAL INC., GEODE CAPITAL MANAGEMENT, LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used